更新于：2024-11-22

Ondansetron Hydrochloride

盐酸昂丹司琼

更新于：2024-11-22

概要

概要

基本信息

简介ZOFRAN®（盐酸昂丹司琼）是一种用于预防恶性肿瘤化疗和手术后恶心和呕吐的药物。ZOFRAN注射液的活性成分为盐酸昂丹司琼，其作用是选择性阻断5-HT3受体类型的血清素。这种作用机制可以通过阻断触发这些症状的大脑信号来有效地预防恶心和呕吐。ZOFRAN注射液是一种透明、无色、无热原、无菌的静脉用药溶液。它于1991年首次在美国由诺华制药公司批准上市。注射液的pH值范围为3.3至4.0。它是一种被广泛使用的药物，可以帮助癌症患者和进行手术的人控制症状，提高他们的生活质量。

药物类型

小分子化药

别名

Ondanseton Hydrochloride、ONDANSETRON、Ondansetron Hydrochloride and Glucose

+ [42]

靶点

5-HT3 receptor

作用机制

5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

University of CalgaryAspen Pharmacare Australia Pty Ltd.

+ [2]

非在研机构

Aquestive Therapeutics, Inc.Transcept Pharmaceuticals, Inc. (Old)山德士有限公司

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1991-01-04),

化疗引起的恶心和呕吐术后恶心呕吐

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C18H22ClN3O2

InChIKeyWRZJOBREMUDSSV-UHFFFAOYSA-N

CAS号103639-04-9

关联

650

项与盐酸昂丹司琼相关的临床试验

NCT05876585 / Not yet recruiting临床3期

A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.

开始日期2025-06-01

申办/合作机构

Adwia Pharmaceuticals Co.

CTRI/2024/09/074272 / Not yet recruitingN/AIIT

Comparative Study of the Efficacy of Intravenous Ondansetron Versus Intravenous Palonosetron in the Prevention of Postoperative Nausea and Vomiting in Elective Laparoscopic Surgeries - NIL

开始日期2024-12-30

申办/合作机构-

CTRI/2024/06/069266 / Not yet recruitingN/AIIT

A comparitive study between Dexamethasone and Ondansetron for prevention of shivering during spinal anesthesia in elective lower abdominal surgeries -a prospective randomised controlled study - Nil

开始日期2024-12-11

申办/合作机构-

100 项与盐酸昂丹司琼相关的临床结果

登录后查看更多信息

100 项与盐酸昂丹司琼相关的转化医学

登录后查看更多信息

100 项与盐酸昂丹司琼相关的专利（医药）

登录后查看更多信息

5,012

项与盐酸昂丹司琼相关的文献（医药）

2025-01-01·Methods in molecular biology (Clifton, N.J.)

Proteogenomics for Non-model Ocean-Derived Fungi

Article

作者: Kumar, Abhishek

Most biological and biomedical experiments are designed and studied using the most common model organisms (MOs) like humans, mice, Escherichia coli, Saccharomyces cerevisiae, Neurospora crassa, worms, fruit flies, zebrafish, and Arabidopsis thaliana. These model organisms have been extensively studied and have a well-established set of genetic, physiological, and other tools available for research. In contrast, non-model organisms (NMOs) are those that are not traditionally used in scientific research and do not have a well-established set of genetic or other biological tools available for their study. The majority of MOs are associated with land habitats but rarely with ocean environments. The ocean forms the largest portion of our planet, yet ocean-derived organisms are the least explored, and these organisms are primarily NMOs. However, these are thrilling living entities, such as ocean-derived fungi (ODF). These ODFs are a diverse group of fungi that live in different ocean sectors, including the ocean, estuaries, and coastal ecosystems. These fungi are found to colonize and adapt to different substrates. They are important decomposers in marine ecosystems, breaking down dead organic matter and recycling nutrients. ODFs have adapted to survive in the unique and challenging conditions of the ocean environment, including high salt concentrations, low nutrient availability, and exposure to waves and currents. ODFs are potent producers of natural compounds with pharmaceutical and industrial applications, such as antibiotics, anticancer agents, antivirals, and enzymes for industrial processes. ODFs are an exciting group of fungi; however, these are the least studied because of the nonavailability of MOs from this group. Hence, there is a massive scope of expanding our current knowledge about ODFs, their genetic traits, potential future drug-producing capabilities, and lifestyle traits.With the advent of next-generation DNA sequencing, there is huge potential for the characterization of the genetic material of ODF as NMOs. Parallel proteomic methods also pose huge potential. A marriage of NGS and proteomic methods generates a new avenue called proteogenomics, which focuses on better annotation of existing genomic data. Both methods are getting cheaper and accessible to the research community for studying the proteogenomics of NMOs. Herein, the proteogenomic protocol development and data analyses are illustrated for the ocean-derived fungus Scopulariopsis brevicaulis.

2024-12-01·Current drug delivery

Development of Polyvinyl Alcohol/Polyethylene Glycol Copolymer-based Orodispersible Films Loaded with Entecavir: Formulation and In vitro Characterization

Article

作者: Shi, Li-Li ; Wei, Teng ; Shi, Ling-Zhi ; Cao, Qin-Ri ; Huang, Xiang-Xiang ; Huo, Ming-Wei ; Liu, Xue-Ai ; Wu, Xin-Hong ; Zhou, Bing-Yu

Purpose::

The aim of the study is to prepare entecavir (ETV)-loaded orodispersible films (ODFs) using polyvinyl alcohol (PVA)/polyethylene glycol (PEG) graft copolymer (Kollicoat® IR) as a film-forming agent, and further to evaluate the dissolution rate, mechanical and physicochemical properties of films.

Methods::

ETV-ODFs were prepared by a solvent casting method. The amount of film-forming agent, plasticizer, and disintegrating agent was optimized in terms of the appearance, thickness, disintegration time and mechanical properties of ODFs. The compatibility between the drug and each excipient was conducted under high temperature (60 °C), high humidity (RH 92.5%), and strong light (4500 Lx) for 10 days. The dissolution study of optimal ODFs compared with the original commercial tablet (Baraclude®) was performed using a paddle method in pH 1.0, pH 4.5, pH 6.8, and pH 7.4 media at 37 °C. The morphology of ODFs was observed via scanning electron microscopy (SEM). The mechanical properties such as tensile strength (TS), elastic modulus (EM), and percentage elongation (E%) of ODFs were evaluated using the universal testing machine. The physicochemical properties of ODFs were investigated using X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier transform infrared spectroscopy (FT-IR).

Results::

The related substances were less than 0.5% under high temperature, high humidity, and strong light for 10 days when ETV was mixed with excipients. The optimal formulation of ODFs was set as the quality ratio of Kollicoat® IR, glycerol, sodium alginate (ALG-Na): TiO2: MCC+CMC-Na: ETV was 60:9:12:1:1:1. The drug-loaded ODFs were white and translucent with excellent stripping property. The thickness, disintegration time, EM, TS, and E% were 103.33±7.02 μm, 25.31±1.95 s, 25.34±8.69 Mpa, 2.14±0.26 Mpa, and 65.45±19.41 %, respectively. The cumulative drug release from ODFs was more than 90% in four different media at 10 min. The SEM showed that the drug was highly dispersible in ODFs, and the XRD, DSC, and FT-IR results showed that there occurred some interactions between the drug and excipients.

Conclusion::

In conclusion, the developed ETV-loaded ODFs showed relatively short disintegration time, rapid drug dissolution, and excellent mechanical properties. This might be an alternative to conventional ETV Tablets for the treatment of chronic hepatitis B.

2024-11-08·TECHNOLOGY AND HEALTH CARE

The intervention effect of psychological care combined with ondansetron, dexamethasone, and promethazine hydrochloride on chemotherapy in breast cancer surgical patients

Article

作者: Dong, Lili ; Li, Xia

BACKGROUND: Breast cancer (BC) is one of the most common malignancies in women and imposes a significant health burden globally. According to data from the World Health Organization, the incidence of BC has been increasing steadily over the years. It has become one of the leading causes of cancer-related death among women worldwide. OBJECTIVE: This work was to evaluate the combined intervention effect of psychological care along with the use of ondansetron, dexamethasone, and promethazine hydrochloride in breast cancer (BC) patients undergoing chemotherapy, including their impact on nausea and vomiting control, quality of life (QoL), and psychological status. METHODS: 64 BC patients undergoing chemotherapy were collected and randomly rolled into a control group (Group C) and an intervention group (Group I). Group C received ondansetron combined with routine psychological support and counseling therapy, while Group I received a combination of ondansetron, dexamethasone, promethazine hydrochloride, and psychological care therapy. Self-assessment scores for anxiety, QoL ratings, white blood cell counts, and incidence of adverse reactions were assessed and compared between the two groups. RESULTS: Group I showed better control of nausea and vomiting versus Group C (P< 0.05). Marked improvements were also observed in the self-rating anxiety scale (SAS) scores, white blood cell counts, and nursing satisfaction in Group I versus Group C (P< 0.05). Nevertheless, the two groups had no significant difference regarding QoL scores (P> 0.05). CONCLUSION: the combination of psychological care with ondansetron, dexamethasone, and promethazine hydrochloride effectively controls nausea and vomiting symptoms in BC patients undergoing chemotherapy and provides higher levels of clinical nursing satisfaction.

237

项与盐酸昂丹司琼相关的新闻（医药）

2024-11-19

·PRNewswire

TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects

TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted TAHO's proposal for a 505(b)(2) NDA submission, based on a single pivotal bioequivalence study comparing the plasma concentration of TAH3311 to the approved tablet formulation. This pivotal, open-label, randomized, crossover trial will enroll 60 subjects. TAH3311 introduces a groundbreaking ODF formulation of apixaban, a widely recognized first-line treatment and gold standard for stroke prevention and thrombosis management. Dr. Howard Lee, Chairman and CEO of TAHO Pharmaceuticals, stated: "Our team at TAHO Pharmaceuticals is dedicated to developing 505(b)(2) new drug formulations to address the clinical disadvantages of existing medications. Apixaban, available exclusively in tablet form, often presents challenges for elderly patients, children, and stroke survivors who have difficulty swallowing. These patients frequently need to crush tablets, mix them with water, and administer them twice daily—a time-consuming and imprecise process that risks dosage loss. TAH3311 overcomes these barriers with a quick-dissolving oral film that melts on the tongue, requires no water, reduces the risk of choking, enhances patient adherence, and alleviates caregiver burden." By addressing the clinical limitations of the tablet form and leveraging the significant market potential of apixaban, TAHO Pharmaceuticals is advancing TAH3311 as a meaningful innovation in anticoagulant therapy. About Apixaban Apixaban (co-developed by BMS and Pfizer under the brand name Eliquis®) is a direct factor Xa inhibitor and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism. With notable safety advantages, it is the leading novel oral anticoagulant (NOAC). According to various industry reports, apixaban was the second-highest-selling drug globally in 2023. About TAHO Pharmaceuticals Ltd. Founded in 2010, TAHO Pharmaceuticals Ltd. leverages its proprietary Transepithelial Delivery System (TDS) to overcome the limitations of existing drugs and develop innovative dosage forms for niche markets. The TDS platform combines advanced transdermal and transmucosal delivery technologies, enabling the development of unique dosage forms such as transdermal patches, ODF, and buccal films. TAHO's diverse product portfolio spans a variety of therapeutic areas, including antithrombotic agents, opioid overdose antidotes, addiction treatments, pediatric ADHD, and chemotherapy-induced antiemetics. Among its notable achievements, TAH4411, an ODF for chemotherapy-induced nausea and vomiting, became the first product of its kind to receive regulatory approval and be commercialized in Japan. Media Contact: TAHO Pharmaceuticals +886-2-2659-8515 [email protected] SOURCE Taho Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期申请上市上市批准

2024-11-14

·GlobeNewswire-Health Care

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effect Marks final study needed for the upcoming FDA meeting for the Phase 3 study design and ongoing partnership discussions Continued excellent safety and tolerability findings, consistent with extensive human use experience with ondansetron GLEN ALLEN, Va., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that it has completed a pharmacokinetics (PK) study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, and therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as less than 10 drinks/drinking day). This data will help the Company optimize study design elements needed for the upcoming Phase 3 clinical trial of AD04. Completion of this study also satisfied an FDA requirement for the upcoming Phase 3 clinical trials of AD04. The study, a single-center, relative bioavailability, open label study, enrolled a total of 30 healthy adult volunteers in two cohorts. Cohort 1 (n=6) was a randomized, open-label, 2-sequence, 2-period crossover study to evaluate the PK variability of ondansetron from AD04 0.33 and 0.99mg. Cohort 2 (n=24) was a randomized, open-label, 6-sequence, 4-period crossover study to evaluate the relative bioavailability of the AD04 0.33mg tablet to a marketed ondansetron 4mg tablet, dose proportionality of ondansetron PK between AD04 0.33 and 0.99mg, and the effect of food on the bioavailability of ondansetron administered as the AD04 0.33mg tablet. The results of this study showed that, as a result of the lower dose, AD04 0.33mg delivered lower ondansetron PK exposure than the marketed reference standard ondansetron 4mg tablet; ondansetron pharmacokinetic exposure increased in proportion to dose across a 3–fold AD04 dose range; and AD04 can be taken in fed or fasted states. Cary Claiborne, President and Chief Executive Officer of Adial commented, "Completion of this study achieves our goal to obtain the data we needed to design a more precise and informed Phase 3 trial protocol, including evaluating the optimal dosing regimen to maximize the efficacy and safety of AD04 in patients with AUD. Its completion is in accord with previous guidance provided by the FDA and is intended to enhance the likelihood of success in our upcoming Phase 3 trial. This relatively short and low-cost study was a key element of our strategy to advance ongoing partnership discussions. Additionally, the study will provide data necessary to support an application for approval of AD04 under a 505(b)(2) regulatory pathway with the FDA. We plan to engage with the FDA during Q4 2024 with the results of this pharmacokinetics study and obtain feedback which will assist with the AD04 Phase 3 study program. This meeting is an important next step to further advancing AD04 towards regulatory approval." About AD04AD04 (0.33mg ondansetron taken orally twice daily) acts upon the 5HT3 pathway and is thought to reduce alcohol craving. This mode of action is distinct from, but complimentary to, the currently approved therapies for AUD. Post-hoc analyses of Adial's prior clinical studies have indicated that patients with mutations in the 5HT3 receptor experience substantial and clinically meaningful reductions in alcohol consumption. The specific mutations that appear to respond to AD04 are single nucleotide polymorphisms (SNPs) on rs1150226-AG ("AG") or rs1176713-GG ("GG") genotypes in the gene that encodes the 5-HT3A receptor subunit. These genes are thought to affect the binding of AD04 to the 5HT3 receptor and its function. Furthermore, in both previous clinical trials, AD04 had similar adverse events to placebo, which further supports that it is likely to be extremely safe and tolerable. Adial has already developed a companion diagnostic test (CDx) to identify the specific genotypes that benefit from AD04. This test was used in its Phase 3 ONWARD study, will be used in future clinical studies, and will be commercially available at the time of AD04's launch. About Adial Pharmaceuticals, Inc.Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com. Forward-Looking StatementsThis communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the pharmacokinetics study data helping the Company optimize study design elements needed for the upcoming Phase 3 clinical trial of AD04, designing a more precise and informed Phase 3 trial protocol, completion of the study providing the data needed to design a more precise and informed Phase 3 trial protocol, including evaluating the optimal dosing regimen to maximize the efficacy and safety of AD04 in patients with AUD, completion of the study enhancing the likelihood of success in the Company’s upcoming Phase 3 trial, advancing ongoing partnership discussions, the study providing data necessary to support an application for approval of AD04 under a 505(b)(2) regulatory pathway with the FDA, plans to engage with the FDA during Q4 2024 with the results of the pharmacokinetics study and obtain feedback which will assist with the AD04 Phase 3 study program, further advancing AD04 towards regulatory approval and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Contact:Crescendo Communications, LLCDavid Waldman / Alexandra SchiltTel: 212-671-1020Email: adil@crescendo-ir.com

临床结果临床3期

2024-11-10

·信狐药迅

一线治疗非小细胞肺癌！上海倍而达三代EGFR抑制剂「瑞齐替尼」新适应症获批上市| 新获批（11.4-11.10）

每周药品注册获批数据，分门别类呈现，一目了然。(11.4-11.10）新药上市申请药品名称企业注册分类受理号甲磺酸瑞齐替尼胶囊上海倍而达药业有限公司1CXHS2400007盐酸凯普拉生片江苏柯菲平医药股份有限公司2.4CXHS2300078聚乙二醇重组人生长激素注射液长春金赛药业有限责任公司2.2CXSS2300057 新药临床申请药品名称企业注册分类受理号CPI-818片嘉兴和剂药业有限公司1CXHL2400893CPI-818片嘉兴和剂药业有限公司1CXHL2400892HYP-6589片四川汇宇海玥医药科技有限公司1CXHL2400863HYP-6589片四川汇宇海玥医药科技有限公司1CXHL2400862LPM682000012片山东绿叶制药有限公司1CXHL2400827LPM682000012片山东绿叶制药有限公司1CXHL2400826LPM682000012片山东绿叶制药有限公司1CXHL2400825BCM899颗粒上海云晟研新生物科技有限公司2.2CXHL2400858BCM899颗粒上海云晟研新生物科技有限公司2.2CXHL2400857注射用艾博韦泰前沿生物药业(南京)股份有限公司2.4CXHL2400865利多卡因丙胺卡因气雾剂江苏联环药业股份有限公司3CYHL2400176雷诺嗪缓释片北京阳光诺和药物研究股份有限公司3CYHL2400173雷诺嗪缓释片北京阳光诺和药物研究股份有限公司3CYHL2400172四价流感重组蛋白疫苗广东华南疫苗股份有限公司1.3CXSL24005289MW2821迈威(上海)生物科技股份有限公司1CXSL2400572ZT006片北京质肽生物医药科技有限公司1CXSL2400569ZT006片北京质肽生物医药科技有限公司1CXSL2400568ZT006片北京质肽生物医药科技有限公司1CXSL2400567ZT006片北京质肽生物医药科技有限公司1CXSL2400566ZT006片北京质肽生物医药科技有限公司1CXSL2400565ZT006片北京质肽生物医药科技有限公司1CXSL2400564CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2400560CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2400559艾米迈托赛注射液铂生卓越生物科技(北京)有限公司1CXSL2400557RJMty19注射液浙江瑞加美生物科技有限公司1CXSL2400553JCXH-211注射液嘉晨西海(杭州)生物技术有限公司1CXSL2400540靶向CD19非病毒PD1定点整合CAR-T细胞注射液上海邦耀生物科技有限公司1CXSL2400533 仿制药申请药品名称企业注册分类受理号维生素B6注射液江苏润恒制药有限公司3CYHS2402860复方聚乙二醇电解质散(II)南京海纳制药有限公司3CYHS2400148复方聚乙二醇电解质散(II)黑龙江博宇制药有限公司3CYHS2303588注射用拉氧头孢钠山东晶辉生物技术有限公司3CYHS2303220注射用拉氧头孢钠山东晶辉生物技术有限公司3CYHS2303219注射用拉氧头孢钠山东晶辉生物技术有限公司3CYHS2303221帕拉米韦注射液陕西博森生物制药股份集团有限公司3CYHS2302082注射用盐酸罗沙替丁醋酸酯郑州维先医药科技有限公司3CYHS2301977硝普钠注射液成都新恒创药业有限公司3CYHS2301634盐酸多巴酚丁胺注射液成都瑞尔医药科技有限公司3CYHS2301571依巴斯汀口服溶液湖南金圃医药科技有限公司3CYHS2301495法莫替丁注射液四川制药制剂有限公司3CYHS2301317盐酸丙卡特罗口服溶液南京艾德加生物制药科技有限公司3CYHS2301170盐酸丙卡特罗口服溶液南京艾德加生物制药科技有限公司3CYHS2301169膦甲酸钠注射液华仁药业股份有限公司3CYHS2301137己酮可可碱注射液武汉海特生物制药股份有限公司3CYHS2301000盐酸昂丹司琼片杭州和泽坤元药业有限公司3CYHS2300910盐酸昂丹司琼片杭州和泽坤元药业有限公司3CYHS2300909盐酸去氧肾上腺素注射液石家庄四药有限公司3CYHS2300901聚乙烯醇滴眼液四川海梦智森生物制药有限公司3CYHS2300897帕米膦酸二钠注射液仁合益康集团有限公司3CYHS2300892头孢氨苄干混悬剂上海金城素智药业有限公司3CYHS2300839盐酸去氧肾上腺素注射液南京恒道医药科技股份有限公司3CYHS2300808甲氨蝶呤片江苏百奥信康医药科技有限公司3CYHS2300574左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300334左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300333左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300332左亚叶酸钙注射液浙江普利药业有限公司3CYHS2300331盐酸多巴酚丁胺注射液浙江沣华医药科技有限公司3CYHS2300301布洛芬混悬滴剂天大医药科技(珠海)有限公司3CYHS2300001国;CYHS2300001米诺地尔搽剂浙江远力健药业有限责任公司3CYHS2201287国;CYHS2201287注射用头孢唑肟钠山东晶辉生物技术有限公司4CYHS2403004注射用头孢唑肟钠山东晶辉生物技术有限公司4CYHS2403003注射用头孢唑肟钠山东晶辉生物技术有限公司4CYHS2403002盐酸曲唑酮缓释片山东京卫制药有限公司4CYHS2401449盐酸曲唑酮缓释片山东京卫制药有限公司4CYHS2401448地夸磷索钠滴眼液江苏远恒药业有限公司4CYHS2400248氧(液态)重庆川维林德气体有限责任公司4CYHS2400178麦考酚钠肠溶片山东新时代药业有限公司4CYHS2303659巴氯芬片重庆士立德医药科技有限公司4CYHS2302507玻璃酸钠滴眼液山东华鲁制药有限公司4CYHS2302277阿戈美拉汀片宝利化(南京)制药有限公司4CYHS2302145左卡尼汀口服溶液浙江长典药物技术开发有限公司4CYHS2302108玻璃酸钠滴眼液安徽环球药业股份有限公司4CYHS2301914玻璃酸钠滴眼液安徽环球药业股份有限公司4CYHS2301913注射用头孢唑肟钠海南全星制药有限公司4CYHS2301760硫辛酸注射液江苏睿实生物科技有限公司4CYHS2301742注射用头孢唑肟钠广州艾奇西新药研究有限公司4CYHS2301641左卡尼汀注射液舒美奇成都生物科技有限公司4CYHS2301604左卡尼汀注射液舒美奇成都生物科技有限公司4CYHS2301603马来酸氟伏沙明片上海理想制药有限公司4CYHS2301497莫匹罗星软膏河南羚锐制药股份有限公司4CYHS2301424二甲双胍恩格列净片天大药业(珠海)有限公司4CYHS2301425马来酸阿法替尼片江苏华阳制药有限公司4CYHS2301281伏立康唑干混悬剂健康元药业集团股份有限公司4CYHS2301217左氧氟沙星滴眼液石家庄凯赛医药科技有限公司4CYHS2301194瑞巴派特片福安药业集团宁波天衡制药有限公司4CYHS2301188熊去氧胆酸胶囊浙江寰领医药科技有限公司4CYHS2300582左氧氟沙星片吉林长白山药业集团股份有限公司4CYHS2300552地夸磷索钠滴眼液南京黄龙生物科技有限公司4CYHS2300464阿加曲班注射液海南葫芦娃药业集团股份有限公司4CYHS2300184克林霉素磷酸酯外用溶液江苏知原药业股份有限公司4CYHS2300147注射用替考拉宁海南倍特药业有限公司4CYHS2300059盐酸环喷托酯滴眼液山东绅联药业股份有限公司4CYHS2300007国;CYHS2300007盐酸美金刚片成都百裕制药股份有限公司4CYHS2201963国;CYHS2201963盐酸乐卡地平片兆科药业(广州)有限公司4CYHS2201840国;CYHS2201840注射用替考拉宁四川汇宇制药股份有限公司4CYHS2201554国;CYHS2201554注射用替考拉宁四川汇宇制药股份有限公司4CYHS2201552国;CYHS2201552注射用多种维生素(12)山东鲁盛制药有限公司4CYHS2201289国;CYHS2201289沙库巴曲缬沙坦钠片山东凤凰制药股份有限公司4CYHS2200423国;CYHS2200423屈螺酮炔雌醇片南通联亚药业股份有限公司4CYHS2200412国;CYHS2200412乌司奴单抗注射液杭州中美华东制药有限公司3.3CXSS2300065 进口申请药品名称企业注册分类受理号甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300032甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300031甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300030甲苯磺酸他拉唑帕利胶囊Pfizer Europe MA EEIG2.4JXHS2300029灌注用盐酸氨酮戊酸己酯Photocure ASA5.1JXHS2300108Acalabrutinib Maleate片AstraZeneca Pty Ltd.5.1JXHS2300077Acalabrutinib Maleate片AstraZeneca Pty Ltd.5.1JXHS2300076阿伐可泮硬胶囊Vifor Fresenius Medical Care Renal Pharma France5.1JXHS2200125国;JXHS2200125纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400015纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400014冻干膀胱灌注用卡介苗(日本株)Japan BCG Laboratory3.1JXSS2400032伊布替尼胶囊Natco Pharma Limited5.2JYHS2300009恩扎卢胺软胶囊Dr. Reddy's Laboratories Limited5.2JYHS2200042国;JYHS2200042AMG 193Amgen Inc.1JXHL2400211 中药相关申请药品名称企业注册分类受理号椒七麝凝胶贴膏湖南九典制药股份有限公司1.1CXZS2300028 注：橙色字体部分结论为不批准或收到通知件；

细胞疗法免疫疗法疫苗申请上市临床申请

100 项与盐酸昂丹司琼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00678	盐酸昂丹司琼	A04AA01	DB00904

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶心	中国	福安药业（集团）股份有限公司	1996-01-01
呕吐	中国	福安药业（集团）股份有限公司	1996-01-01
放疗引起的恶心和呕吐	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-04-17
化疗引起的恶心和呕吐	美国	Sandoz, Inc.	1991-01-04
术后恶心呕吐	美国	Sandoz, Inc.	1991-01-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晕厥	临床3期	加拿大	University of Calgary	2024-12-01
酒精使用障碍	临床3期	保加利亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	克罗地亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	爱沙尼亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	芬兰	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	拉脱维亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	波兰	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	瑞典	Adial Pharmaceuticals, Inc.	2020-02-01
急性胃肠炎	临床3期	加拿大	University of Calgary	2019-09-04
腹泻	临床3期	加拿大	University of Calgary	2019-09-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW	N/A	腹泻	-	Ondansetron 4mg	壓醖艱醖廠夢築糧壓築(選製網餘餘壓鬱鹹築積) = Adverse events were significantly higher in non-responders compared to responders (p=0.02) 築壓廠構襯鹹鹽選網獵 (遞遞鑰壓築艱襯蓋鹽獵 ) 更多	-	2024-10-13
ASCO2024	N/A	-	-	ondansetron	網顧鏇構繭淵築鹽鬱構(構範憲簾蓋鏇構糧鏇齋) = 簾窪夢憲選衊遞選鏇襯網選夢膚製觸廠簾鬱壓 (憲廠積襯願衊膚糧壓積 ) 更多	-	2024-05-24
				ondansetron	網顧鏇構繭淵築鹽鬱構(構範憲簾蓋鏇構糧鏇齋) = 夢艱觸襯積網製蓋襯網網選夢膚製觸廠簾鬱壓 (憲廠積襯願衊膚糧壓積 ) 更多
NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	顧鏇顧蓋鑰膚選鹽衊衊(鬱廠選廠鏇齋鏇簾憲壓) = 齋壓夢衊簾鬱糧遞鏇夢範艱範艱選齋糧選鏇網 (醖夢積夢衊膚網衊窪獵, 艱選範壓構齋遞壓淵艱 ~ 艱窪繭遞範製獵艱積壓) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	顧鏇顧蓋鑰膚選鹽衊衊(鬱廠選廠鏇齋鏇簾憲壓) = 窪壓艱鑰鑰廠衊獵夢糧範艱範艱選齋糧選鏇網 (醖夢積夢衊膚網衊窪獵, 鹹壓蓋糧積觸廠遞鏇窪 ~ 艱餘鑰製淵糧壓艱築網) 更多
NCT05098067 (CTgov)	临床2期	妊娠剧吐 \| 恶心 \| 妊娠呕吐	30	Lactated Ringers, Intravenous+Metoclopramide+Capsaicin Topical Cream+Ondansetron (Intervention Group)	糧鑰膚網獵壓艱獵艱膚(構壓獵網蓋鹽願餘範遞) = 選顧衊鏇構齋艱蓋蓋觸鏇獵壓願構鏇糧鹹鏇構 (獵鬱艱繭壓鏇顧齋廠膚, 齋遞淵簾壓鑰遞鑰網蓋 ~ 網選鑰齋齋鏇憲顧觸蓋) 更多	-	2024-02-07
				Lactated Ringers, Intravenous+Metoclopramide+Ondansetron (Placebo Group)	糧鑰膚網獵壓艱獵艱膚(構壓獵網蓋鹽願餘範遞) = 襯醖窪鬱鹽顧餘遞醖鹽鏇獵壓願構鏇糧鹹鏇構 (獵鬱艱繭壓鏇顧齋廠膚, 簾餘選網憲顧網廠範壓 ~ 鏇醖獵廠醖繭構壓遞積) 更多
NCT03237611 (CTgov)	临床2期	化疗引起的恶心和呕吐	15	Ondansetron 16 MG+Aprepitant 125 mg+Dexamethasone+Fosaprepitant 115 MG	醖範鬱網築鬱膚顧築簾(獵製廠蓋製獵鑰遞簾願) = 鏇製積鹽糧願簾製構繭遞膚糧鬱襯醖鬱網願顧 (夢築鏇鏇鏇構鹽簾鏇蓋, 餘窪顧窪廠繭壓顧廠艱 ~ 鑰顧鑰膚餘製選廠膚齋) 更多	-	2023-11-13
NCT02991456 (CTgov)	临床2期	放疗引起的恶心和呕吐 \| 胶质瘤	48	Ondansetron+Rolapitant (Sequence A)	齋網齋壓艱壓築簾廠窪(觸遞壓範繭獵憲築齋鹹) = 壓齋衊顧膚鏇膚鏇獵顧製醖網鏇齋襯艱鏇鏇簾 (憲蓋鏇鹹艱製醖構鏇製, 鏇壓廠築壓壓構艱觸鹽 ~ 襯淵積築獵獵膚膚醖鏇) 更多	-	2023-07-11
				Ondansetron+Rolapitant (Sequence B)	齋網齋壓艱壓築簾廠窪(觸遞壓範繭獵憲築齋鹹) = 範糧蓋糧構築衊獵鹽築製醖網鏇齋襯艱鏇鏇簾 (憲蓋鏇鹹艱製醖構鏇製, 衊醖獵觸鹽襯網廠鏇襯 ~ 糧糧窪糧衊製鹽製淵醖) 更多
NCT03239210 (CTgov)	临床4期	Tourette 综合征 \| 强迫症	110	Ondansetron (Ondansetron (OND))	鏇糧觸構鏇觸獵憲齋觸(範選衊鬱選繭憲鏇顧蓋) = 觸壓鏇獵顧鹽製鑰蓋齋鑰膚鹽繭衊鬱艱餘糧選 (夢鬱鏇選網鏇鹽衊顧壓, 範顧糧醖廠窪壓糧壓顧 ~ 網鏇鑰蓋範淵艱艱鏇衊) 更多	-	2023-07-03
				Placebo (Placebo (PL))	鏇糧觸構鏇觸獵憲齋觸(範選衊鬱選繭憲鏇顧蓋) = 憲夢觸築醖醖鏇艱夢觸鑰膚鹽繭衊鬱艱餘糧選 (夢鬱鏇選網鏇鹽衊顧壓, 餘顧淵鏇築壓遞膚襯積 ~ 襯餘築繭築遞衊願廠鏇) 更多
NCT03578081 (CTgov)	临床3期	恶心 \| 化疗引起的恶心和呕吐 \| 肿瘤 ... 更多	690	Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine))	淵鑰夢襯鏇窪選齋鑰選(獵蓋顧觸艱網醖願壓簾) = 構遞鹽鹹鹽淵膚廠膚齋繭遞淵鑰鏇襯淵積壓醖 (簾蓋積廠繭襯觸遞窪願, 築蓋鏇壓積鏇選齋鑰顧 ~ 淵積鏇膚製顧獵淵簾衊) 更多	-	2023-05-08
				Placebo+Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone (Arm II (Placebo, Olanzapine))	淵鑰夢襯鏇窪選齋鑰選(獵蓋顧觸艱網醖願壓簾) = 範觸鹹窪鏇鑰鹹蓋醖築繭遞淵鑰鏇襯淵積壓醖 (簾蓋積廠繭襯觸遞窪願, 遞願願網醖餘淵淵鬱鏇 ~ 構鏇簾觸襯願餘淵衊遞) 更多
ISRCTN17508514 (Pubmed)	临床3期	腹泻型肠易激综合征	400	Ondansetron 4 mg	艱糧醖築築願獵範蓋鑰(願顧壓獵遞醖糧築鹽廠) = 蓋廠積壓壓鏇糧獵鹽簾範觸願衊繭襯遞鑰餘願 (範壓壓遞膚積獵獵製簾, 24.7% ~ 56.4%) 更多	-	2023-03-03
				Placebo	艱糧醖築築願獵範蓋鑰(願顧壓獵遞醖糧築鹽廠) = 構齋齋壓範鑰築糧窪襯範觸願衊繭襯遞鑰餘願 (範壓壓遞膚積獵獵製簾, 14.5% ~ 41.3%) 更多
NCT03817970 (ASN2022)	临床3期	肾脏毒性	23	Ondansetron 8 mg p.o.	窪鬱襯願範蓋蓋觸遞壓(鹽獵憲廠簾艱齋窪製鏇) = 獵範壓鏇壓廠範遞顧簾範夢衊餘鏇製鹽餘遞繭 (鏇蓋構醖網繭遞膚選繭 ) 更多	不佳	2022-11-04
				Palonosetron 0.25 mg i.v.	窪鬱襯願範蓋蓋觸遞壓(鹽獵憲廠簾艱齋窪製鏇) = 繭鹽鑰窪壓襯醖鏇廠憲範夢衊餘鏇製鹽餘遞繭 (鏇蓋構醖網繭遞膚選繭 ) 更多